The Non-Alcoholic Steatohepatitis Biomarkers Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Non-Alcoholic Steatohepatitis Biomarkers Market?
The market size of the non-alcoholic steatohepatitis biomarkers has seen exponential growth recently. It was valued at $1.36 billion in 2024 and is predicted to increase to $1.7 billion in 2025. This reflects a compound annual growth rate (CAGR) of 24.8%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Non-Alcoholic Steatohepatitis Biomarkers Industry?
The Non-Alcoholic Steatohepatitis Biomarkers market is expected to reach $3.86 billion by 2029, growing at a compound annual growth rate (CAGR) of 22.8%.
Download Your Free Sample of the 2025 Non-Alcoholic Steatohepatitis Biomarkers Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Non-Alcoholic Steatohepatitis Biomarkers Market?
The key drivers in the non-alcoholic steatohepatitis biomarkers market are:
• Emergence of novel therapies in the field
• Expansion of precision medicine approaches
• Integration of multi-omics data for enhanced diagnosis and treatment
• Enhanced patient engagement and advocacy initiatives
Global Market Segmentation: Identifying Major Non-Alcoholic Steatohepatitis Biomarkers Industry Segments
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Pre-order the 2025 Non-Alcoholic Steatohepatitis Biomarkers Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Non-Alcoholic Steatohepatitis Biomarkers Market?
The key trends in the non-alcoholic steatohepatitis biomarkers market are:
• The integration of artificial intelligence and multi-omics data is shaping the future of thenon-alcoholic steatohepatitis biomarkers market.
• The use of telemedicine and remote monitoring techniques is becoming a significant trend.
• Global collaborations in research and the expansion of precision medicine approaches are emerging trends in the industry.
• Technological advancements in biomarker discovery and the inclusion of imaging biomarkers are influencing the market's future.
Who Are the Top Competitors & Leading Players in the Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies in the non-alcoholic steatohepatitis biomarkers market are:
• Genfit SA
• Prometheus Laboratories Inc.
• Siemens Medical Solutions USA Inc.
• BioPredictive
• Quest Diagnostics
• AstraZeneca Plc.
• Laboratory Corporation of America Holdings
• Pfizer Inc.
• Bristol-Myers Squibb Company
• NGM Biopharmaceuticals Inc.
• Gilead Sciences Inc.
• Perspectum Diagnostics Ltd.
• One Way Liver SL
• Enterome SA
• Echosens SA
• Cisbio Bioassays SAS
• Celerion Inc.
• Boehringer Ingelheim GmbH Inc.
• Exalenz Bioscience Ltd.
• Novartis AG
• Novo Nordisk A/S
• Allergan PLC.
• Glympse Bio
• HistoIndex Pte Ltd
• Cirius Therapeutics
• Intercept Pharmaceuticals
• Viking Therapeutics
• Madrigal Pharmaceuticals
• Galmed Pharmaceuticals
• Immuron Ltd
• Metacrine
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024
